+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gemcitabine HCL Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2027

  • ID: 4851228
  • Report
  • June 2019
  • Region: Global
  • 210 pages
  • Transparency Market Research

Enquire about COVID-19 updates for this product.

Enquire Now

Gemcitabine HCl Market: Report Description

A recent report analyzes the impact of past and present landscape on the future of the global gemcitabine HCl market. The study offers detailed information on the latest trends and opportunities for key stakeholders in the gemcitabine HCl market during the period of 2019-2027.

The report helps readers gauge the various dynamics of the gemcitabine HCl market, and provides actionable insights that can arm key stakeholders in the gemcitabine HCl market with the necessary information to take critical and well-informed decisions. This study also provides a key indicator analysis to define the growth prospects of the gemcitabine HCl market, and future estimates regarding the development of the gemcitabine HCl market in terms of value and volume.

The report provides exclusive data on the sales of gemcitabine HCl and the potential increase across different geographical regions. The study also includes thorough analysis of the existing competitive landscape, and offers detailed insights on product innovation and business development strategies adopted by key players in the gemcitabine HCl market.

Key Questions Answered in the Gemcitabine HCl Market Report

The report details a qualitative and quantitative breakdown of the gemcitabine HCl market, based on thorough research about the macro- and micro-economic aspects influencing the growth of the gemcitabine HCl market. Comprehensive information featured in the report can provide answers to various questions for industry participants, in order to enhance their decision-making processes. Some of these questions include:

  • How is the regulatory scenario in developed countries impacting the gemcitabine HCl market?
  • What are the potential threats faced by key stakeholders in the gemcitabine HCl market?
  • How will the historical prospects of the gemcitabine HCl market influence changes in the future?
  • What are the imperative strategies adopted by leading players to strengthen their position in the gemcitabine HCl market?
  • How will DMF fillings by India- and China-based companies influence the expansion of the gemcitabine HCl market?
  • What are the R&D strategies used by key manufactures to receive approval of their products?
  • What are the upcoming commercial prospects in the gemcitabine HCl market?

Gemcitabine HCl Market: Research Methodology

The research methodology followed by Analysts to obtain detailed information and estimate the overall size of the gemcitabine HCl market involves conducting thorough research. Industry-based information acquired through secondary resources are verified by conducting interviews with relevant stakeholders, which helped the analysts deliver extensive insights on how the gemcitabine HCl market will grow and expand during the course of the forecast period.

Around 34% of primary research for the development of the emcitabine HCl market report involved interviewing industry experts such as CEOs, presidents, directors, chairmen, vice presidents, and chief medical officers. Nearly 66% of primary respondents involved generic or branded medicine providers, scientists, physicians, oncology surgeons, healthcare professionals, surgeons, medical assistants, and assistant medical directors, along with product and brands managers of companies operating in the sales of gemcitabine HCl.

For secondary research, analysts have referred to company websites, white papers, annual reports, and financial report to confirm the accuracy of the future trends and opportunities of the gemcitabine HCl market. Other secondary resources include the Organization for Economic Co-operation and Development, Pubmed, Department of Health and Human Services, National Center for Health Statistics U.S., National Institute for Health and Clinical Excellence, and Association for Accessible Medicines.

Note: Product cover images may vary from those shown
1. Global Gemcitabine HCL Market - Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology
2.1. Gemcitabine HCL Market Definition
2.2. Gemcitabine HCL Market Taxonomy

3. Executive Summary : Global Gemcitabine HCL Market
3.1. Market Overview
3.2. Introduction
3.3. Type Definition
3.3.1. Industry Evolution/Developments
3.4. Overview
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Global Gemcitabine HCL Market Analysis and Forecast
3.6.1. Market Revenue Projections (US$ Mn)
3.7. Porter’s Five Force Analysis

4. Key Insights
4.1. Disease Prevalence & Incidence Rate globally with key countries
4.2. Regulatory Scenario by Region/globally
4.3. Pipeline Analysis
4.4. Key Mergers & Acquisitions
4.5. Pricing Analysis of Finished products
4.6. Overview of Manufacturers
4.7. Consumption of Gemcitabine HCL(Volume) per Region (2018)
4.8. Prices by Key Manufacturers(US$/kg)

5. Global Gemcitabine HCL Market Analysis and Forecast, By Type
5.1. Introduction
5.1.1. Introduction & Definition By Type
5.1.2. Key Findings/Developments By Type
5.2. Market Size (US$ Mn) Forecast By Type
5.2.1. Branded
5.2.2. Generic
5.3. Market Attractiveness Analysis By Type

6. Global Gemcitabine HCL Market Analysis and Forecast, By Application
6.1. Introduction
6.1.1. Introduction & Definition By Application
6.1.2. Key Findings/Developments By Application
6.2. Market Size (US$ Mn) Forecast By Application
6.2.1. Pancreatic Cancer
6.2.2. Breast Cancer
6.2.3. Ovarian Cancer
6.2.4. Non-small-cell Lung Carcinoma (NSCLC)
6.2.5. Other

7. Global Gemcitabine HCL Market Analysis and Forecast, By End User
7.1. Introduction
7.1.1. Introduction & Definition By End User
7.1.2. Key Findings/Developments By End User
7.2. Market Size (US$ Mn) Forecast By End User
7.2.1. Hospitals
7.2.2. Cancer Centers
7.2.3. Others

8. Global Gemcitabine HCL Market Analysis and Forecast, By Region/sub-Region
8.1. Introduction
8.1.1. Introduction & Definition
8.1.2. Key Findings/Developments
8.2. Market Size (US$ Mn) Forecast By Region/Sub-Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East and Africa (MEA)
8.3. Market Attractiveness Analysis By Region/Sub-Region

9. North America Gemcitabine HCL Market Analysis and Forecast
9.1. Introduction
9.1.1. Introduction & Definition
9.1.2. Key Findings/Developments
9.2. Market Size (US$ Mn) Forecast By Country
9.2.1. U.S.
9.2.2. Canada
9.3. Market Size (US$ Mn) Forecast By Type
9.3.1. Branded
9.3.2. Generic
9.4. Market Size (US$ Mn) Forecast By Application
9.4.1. Pancreatic Cancer
9.4.2. Breast Cancer
9.4.3. Ovarian Cancer
9.4.4. Non-small-cell Lung Carcinoma (NSCLC)
9.4.5. Other
9.5. Market Size (US$ Mn) Forecast By End User
9.5.1. Hospitals
9.5.2. Cancer Centers
9.5.3. Others
9.6. Market Attractiveness Analysis
9.6.1. By Country
9.6.2. By Type
9.6.3. By Application
9.6.4. By End User

10. Europe Gemcitabine HCL Market Analysis and Forecast
10.1. Introduction
10.1.1. Introduction & Definition
10.1.2. Key Findings/Developments
10.2. Market Size (US$ Mn) and Forecast By Country /Sub-Region
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. Spain
10.2.5. U.K.
10.2.6. Rest of Europe
10.3. Market Size (US$ Mn) Forecast By Type
10.3.1. Branded
10.3.2. Generic
10.4. Market Size (US$ Mn) Forecast By Application
10.4.1. Pancreatic Cancer
10.4.2. Breast Cancer
10.4.3. Ovarian Cancer
10.4.4. Non-small-cell Lung Carcinoma (NSCLC)
10.4.5. Other
10.5. Market Size (US$ Mn) Forecast By End User
10.5.1. Hospitals
10.5.2. Cancer Centers
10.5.3. Others
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Type
10.6.3. By Application
10.6.4. By End User

11. Asia Pacific Gemcitabine HCL Market Analysis and Forecast
11.1. Introduction
11.1.1. Introduction & Definition
11.1.2. Key Findings/Developments
11.2. Market Size (US$ Mn) and Forecast By Country/Region
11.2.1. China
11.2.2. India
11.2.3. Japan
11.2.4. Australia and New Zealand
11.2.5. Rest of Asia-Pacific
11.3. Market Size (US$ Mn) Forecast By Type
11.3.1. Branded
11.3.2. Generic
11.4. Market Size (US$ Mn) Forecast By Application
11.4.1. Pancreatic Cancer
11.4.2. Breast Cancer
11.4.3. Ovarian Cancer
11.4.4. Non-small-cell Lung Carcinoma (NSCLC)
11.4.5. Other
11.5. Market Size (US$ Mn) Forecast By End User
11.5.1. Hospitals
11.5.2. Cancer Centers
11.5.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Type
11.6.3. By Application
11.6.4. By End User

12. Latin America Gemcitabine HCL Market Analysis and Forecast
12.1. Introduction
12.1.1. Introduction & Definition
12.1.2. Key Findings/Developments
12.2. Market Size (US$ Mn) and Forecast By Country
12.2.1. Brazil
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Market Size (US$ Mn) Forecast By Type
12.3.1. Branded
12.3.2. Generic
12.4. Market Size (US$ Mn) Forecast By Application
12.4.1. Pancreatic Cancer
12.4.2. Breast Cancer
12.4.3. Ovarian Cancer
12.4.4. Non-small-cell Lung Carcinoma (NSCLC)
12.4.5. Other
12.5. Market Size (US$ Mn) Forecast By End User
12.5.1. Hospitals
12.5.2. Cancer Centers
12.5.3. Others
12.6. Market Attractiveness Analysis
12.6.1. By Country
12.6.2. By Type
12.6.3. By Application
12.6.4. By End User

13. MEA Gemcitabine HCL Market Analysis and Forecast
13.1. Introduction
13.1.1. Introduction & Definition
13.1.2. Key Findings/Developments
13.1.3. Key Regulations
13.2. Market Size (US$ Mn) Forecast By Country
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of MEA
13.3. Market Size (US$ Mn) Forecast By Type
13.3.1. Branded
13.3.2. Generic
13.4. Market Size (US$ Mn) Forecast By Application
13.4.1. Pancreatic Cancer
13.4.2. Breast Cancer
13.4.3. Ovarian Cancer
13.4.4. Non-small-cell Lung Carcinoma (NSCLC)
13.4.5. Other
13.5. Market Size (US$ Mn) Forecast By End User
13.5.1. Hospitals
13.5.2. Cancer Centers
13.5.3. Others
13.6. Market Attractiveness Analysis
13.6.1. By Country
13.6.2. By Type
13.6.3. By Application
13.6.4. By End User

14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company
14.2.1. Eli Lilly and Company
14.2.2. Teva Pharmaceutical Industries Ltd.
14.2.3. Accord-UK Ltd.
14.2.4. Pfizer, Inc.
14.2.5. Mylan N.V.
14.2.6. Sun Pharmaceutical Industries Ltd.
14.2.7. Fresenius Kabi AG
14.2.8. Dr. Reddy’s Laboratories Ltd.
14.2.9. Ingenus Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll